News
Carcinogen Concern Leads To Pfizer Drug Recall From The US
Pfizer's recall saga has now reached the United States, after elevated concentrations of potential carcinogens forced the company to pull multiple products in Canada. After testing revealed quantities of a nitrosamine—Nnitroso-quinapril—above daily recommended limits, Pfizer is recalling five lots...
News
Catalent Buys A NJ Cell Therapy Facility For $44.5 Million
Catalent, the high-flying CDMO, is buying a cell therapy unit on the East Coast, only days after spending $350 million to strengthen up biologics production in Indiana.
Catalent announced on April 25th that it had paid $44.5 million for Erytech...
News
First Malaria Vaccine Protects Around A Million African Kids
More than a million children in Ghana, Kenya, and Malawi have been given one or more doses of the world’s first malaria vaccine, owing to a pilot programme supervised by WHO, as World Malaria Day approaches this year. The...
News
NorthX Biologics signs GMP manufacturing collaboration agreement with Abera Bioscience
Sweden-based NorthX Biologics, which focuses on process development and large-scale production of advanced biological drugs, has signed a collaboration agreement with Abera Bioscience for upscaling and GMP manufacturing of its vaccine candidate against pneumococcus, Ab-01.12.
NorthX has recently established an...
News
Tower Cold Chain wins Queen’s Award for International Trade
Pharmaceutical temperature-controlled specialist Tower Cold Chain has been honoured with a Queen’s Award for Enterprise, the UK’s highest accolade for business success. The company won its award for International Trade for Outstanding Short Term Growth in export sales made...
News
Ontario and Quebec become the first provinces to list Kesimpta for the treatment of adults with relapsing remitting multiple sclerosis
Novartis Pharmaceuticals Canada Inc. is pleased to announce that PrKesimpta® (ofatumumab) is now covered under the Ontario Exceptional Access Program (EAP) and included on the Régie de l’assurance maladie du Québec (RAMQ) List of Medications as an Exceptional Medication for...
News
FDA Wants To Know How Patients, Doctors Decide Prescriptions
The FDA's Office of Prescription Medicine Promotion (OPDP) intends to know how patients and doctors consider the risks and benefits of a new prescription medicine before starting it. What factors influence treatment decisions, and how do people choose one medication...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read